glp-1 2026 Receptor Agonist Market Forecast Report, 2033 Beyond GLP-1Rs: emerging targets poised
Description
He shared one idea that could cut costs by 30% in a year.
GLP-1 use is rebalancing entire shopping baskets
Hims & Hers is launching a tracker of GLP-1 shortages to push back against the FDA's recent moves to end compounding copycats of the blockbuster drugs.
Snelle verzending!
The GLP-1 arena is currently dominated by two giants, Novo Nordisk and Eli Lilly, forming a duopoly in this high-growth field
This brief examines the financialized business model of Novo Nordisk and Eli Lilly for the leading GLP-1 products Ozempic, Rybelsus, and Wegovy (semaglutide) and Mounjaro and Zepbound (tirzepatide)
